Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14705862 | 0.85 | SMN1; SMN2 (0.40) | SMN1; SMN2IKBKEALDH1A1GAA | |
| SCHEMBL23854651 | 0.78 | TSHR (0.50) | IKBKEHPGDMAOBPIK3CDPIK3CA | |
| SCHEMBL4011503 | 0.78 | DYRK1A (0.49) | SMN1; SMN2MAPTALDH1A1HPGDGAA | |
| SCHEMBL1149631 | 0.76 | HCAR2 (0.64) | — | |
| SCHEMBL12726140 | 0.76 | DAO (0.45) | RAB9ANPC1SMN1; SMN2DAOMAPT | |
| SCHEMBL9080444 | 0.75 | NPC1 (0.45) | RAB9ANPC1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL16234233 | 0.74 | DAO (0.55) | DAOSOD1 | |
| SCHEMBL12858206 | 0.73 | HCAR2 (0.53) | SMN1; SMN2DAOMAPTALDH1A1MAOB | |
| SCHEMBL3499891 | 0.73 | HPGD (0.59) | ALDH1A1HPGD | |
| SCHEMBL3941256 | 0.72 | KCNH2 (0.50) | RAB9ANPC1SMN1; SMN2IKBKEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101501030-A | Pyrimidine derivatives useful in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | RAB9A 1172/4885NPC1 13/4885SMN1; SMN2 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.